A month has gone by since the last earnings report for Cencora (COR) . Shares have lost about 6.3% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Cencora due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Cencora, Inc. before we dive into how investors and analysts have reacted as of late.COR ...

Group 1: Stock Performance and Rankings - Pediatrix Medical Group, Inc. (MD) has a Zacks Rank 1 and its earnings estimate increased by 15.7% over the last 60 days [1] - Pediatrix's shares gained 35.4% over the last three months, significantly outperforming the S&P 500's 2.9% increase [2] - La-Z-Boy Incorporated (LZB) also holds a Zacks Rank 1 with a 3.2% increase in its earnings estimate over the last 60 days [2] - La-Z-Boy's shares increased by 3% over the last three months, matching the S&P 500's performance [2] - Grupo Cibest S.A. (CIB) has a Zacks Rank 1 and its earnings estimate rose by 8.7% over the last 60 days [3] - Grupo Cibest's shares increased by 22.1% over the last three months, again outperforming the S&P 500 [3] Group 2: Momentum Scores - Pediatrix Medical Group possesses a Momentum Score of A, indicating strong momentum characteristics [2] - La-Z-Boy has a Momentum Score of B, reflecting moderate momentum [2] - Grupo Cibest also holds a Momentum Score of B, suggesting a similar level of momentum as La-Z-Boy [3]

Group 1 - Amer Sports, Inc. has seen a Zacks Consensus Estimate increase of 8.3% for its current year earnings over the last 60 days [1] - Intuitive Surgical, Inc. has experienced a 5.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Pediatrix Medical Group, Inc. has had a significant increase of 15.7% in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Seanergy Maritime Holdings Corp. has seen a remarkable 66.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Grupo Cibest S.A. has experienced an 8.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Core Insights - Three stocks are highlighted with a buy rank and strong value characteristics for investors to consider on November 24 Group 1: John B. Sanfilippo & Son, Inc. (JBSS) - The company operates in the tree nuts and peanuts sector and holds a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 7.8% over the last 60 days [1] - The price-to-earnings ratio (P/E) is 11.84, significantly lower than the industry average of 29.50 [1] - The company has a Value Score of A [1] Group 2: Grupo Cibest S.A. (CIB) - This company provides banking services and products and also holds a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 8.7% over the last 60 days [2] - The price-to-earnings ratio (P/E) is 7.81, compared to 24.24 for the S&P 500 [2] - The company has a Value Score of B [2] Group 3: Pediatrix Medical Group, Inc. (MD) - The company specializes in newborn care, maternal-fetal medicine, and pediatric subspecialty services, holding a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 15.7% over the last 60 days [3] - The price-to-earnings ratio (P/E) is 11.19, lower than the S&P 500 average of 24.24 [3] - The company has a Value Score of B [3]

Core Viewpoint - Pediatrix Medical Group, Inc. (NYSE:MD) is identified as a promising small-cap stock, with a price target increase from $17 to $24 by Truist Financial, maintaining a Buy rating [1]. Financial Performance - The company experienced a 33.59% increase in share price following the release of its fiscal Q3 2025 results, which showed quarterly revenue of $492.88 million, a decrease of 3.58% year-over-year, but exceeding analysts' estimates by $16.43 million [2]. - Earnings per share (EPS) for the quarter was $0.67, surpassing consensus estimates by $0.20 [2]. Revenue Analysis - The revenue decline was attributed to a portfolio restructuring activity costing approximately $54 million. However, this was mitigated by an 8% growth in same-unit performance, a 7.5% increase in same-unit pricing, and a 40 basis points rise in patient service volumes [3]. EBITDA and Guidance - Adjusted EBITDA for the quarter reached $87 million, exceeding management's expectations, driven by positive pricing outcomes, collections, and expense controls [4]. - The company raised its full-year adjusted EBITDA guidance to a range of $270 million to $290 million, up from the previous range of $245 million to $255 million [4]. Company Overview - Pediatrix Medical Group, Inc. is a leading provider of specialized physician services for women, babies, and children, focusing on newborn, maternal-fetal, and pediatric subspecialty care [5].

Core Viewpoint - Icon PLC reported quarterly earnings of $3.31 per share, exceeding the Zacks Consensus Estimate of $3.28 per share, but down from $3.35 per share a year ago, indicating a slight decline year-over-year [1] - The company achieved revenues of $2.04 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.03% and showing a marginal increase from $2.03 billion year-over-year [2] Group 1: Earnings Performance - Icon PLC's earnings surprise was +0.91%, and it has surpassed consensus EPS estimates in all four of the last quarters [1][2] - The company had a previous quarter earnings expectation of $3.18 per share, but it reported $3.26, resulting in a surprise of +2.52% [1] Group 2: Revenue Performance - The company has topped consensus revenue estimates three times over the last four quarters, indicating a consistent performance trend [2] - The current consensus EPS estimate for the upcoming quarter is $3.45 on revenues of $1.99 billion, and for the current fiscal year, it is $13.19 on revenues of $7.99 billion [7] Group 3: Market Performance and Outlook - Icon PLC shares have declined approximately 7.8% since the beginning of the year, contrasting with the S&P 500's gain of 14.5% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current unfavorable estimate revisions leading to a Zacks Rank 4 (Sell) [6] Group 4: Industry Context - The Medical Services industry, to which Icon PLC belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Select Medical Holdings Corporation (SEM) has experienced significant underperformance in 2025, with shares down 33.4% year to date, compared to the industry's 29.7% gain and the S&P 500's 14.2% growth. The stock is currently trading at $12.55, which is 69.4% below its 52-week high of $40.98 [1]. Group 1: Challenges Facing SEM - The Critical Illness Recovery Hospital unit has shown weakness, with admissions declining by 1% in 2023, 1.2% in 2024, and 0.5% in the first half of 2025. This has led to lower patient days and revenue per patient day, resulting in a 28% year-over-year decrease in operating income [3]. - Rising costs are a concern, with expenses increasing by 7.9% in 2024 and 3.4% in the first half of 2025, with no signs of slowing down. Additionally, uncertainty regarding future government medical aid adds pressure [4]. - SEM's trailing 12-month return on equity is 8.9%, significantly below the industry average of 21.1%, indicating weak capital efficiency [4]. - The company's net debt-to-capital ratio is high at 47.2%, with long-term debt at $1.8 billion and only $52.3 million in cash as of June 30, 2025 [5]. Group 2: Financial Projections - The Zacks Consensus Estimate projects SEM's 2025 revenues at $5.37 billion, reflecting an 18.9% year-over-year decline, followed by a 4.9% recovery in 2026. EPS is expected to be $1.17 in 2025, up 24.5%, with an additional 14.3% increase in 2026 [6][7]. Group 3: Positive Aspects - The Rehabilitation Hospital segment is performing well, with occupancy at 82% in the first half of 2025. Admissions and patient days increased by 8.1% and 6.4%, respectively, while operating income rose by 12.1% in 2024 and 16.1% in the first half of 2025, maintaining margins above 20% [8]. - Operating cash flow was strong, at $517.9 million in 2024 and $106.8 million in the first half of 2025. The company plans to add 412 more beds between 2025 and mid-2027, which could enhance growth [9]. - SEM's valuation appears attractive, trading at a forward P/E of 9.69X, below its five-year median of 12.75X and the industry average of 13.55X, suggesting potential for a rebound as fundamentals stabilize. The company currently holds a Value Score of A [10]. Group 4: Overall Assessment - SEM is facing significant challenges, including poor performance in its Critical Illness Recovery Hospitals, rising costs, high leverage, and lower returns compared to peers. However, the Rehabilitation Hospital segment shows promise with healthy occupancy and cash generation. The company's undervalued trading multiples indicate potential upside if execution improves. The stock is rated Zacks Rank 3 (Hold), suggesting that investors may consider maintaining their current positions [11].

Core Insights - Danaher Corporation (DHR) is experiencing strong growth in its bioprocessing business, with orders increasing for the eighth consecutive quarter, driven by rising demand for consumables from large pharmaceutical customers in Europe. The company expects core revenues from this segment to grow in high single digits year-over-year for 2025 [1][10] - The Biotechnology segment is also performing well, with core revenues increasing by 6% year-over-year, supported by solid demand for monoclonal antibodies (mAbs) [2][10] - The Diagnostics segment is recovering, with core revenues increasing by 2% year-over-year, driven by demand for non-respiratory disease tests and growth in the Beckman Colter Diagnostics unit [3][10] - Danaher is focused on acquisitions to expand its customer base and product offerings, with the acquisition of Abcam in December 2023 enhancing its Life Sciences segment. This acquisition contributed to a 1.5% revenue increase in the Life Sciences segment for the second quarter of 2025 [4][10] - The company is committed to returning value to shareholders through dividends and share buybacks, having paid out $423 million in dividends in the first half of 2025, and increasing its dividend by 18.5% to 32 cents per share in February 2025 [5] - Despite positive trends, the Life Sciences segment faced a 2.5% decline in core revenues year-over-year due to lower demand in academic and government markets, as well as a sales decline in the filtration business related to energy markets [9][10] - Danaher has high debt levels, exiting the second quarter of 2025 with long-term debt of $16.9 billion, a 5.6% increase sequentially, and current liabilities of $6.8 billion, which exceed cash equivalents of approximately $3 billion [11]

Market Overview - The market received a boost from Fed Chair Jerome Powell's Jackson Hole speech, indicating potential rate cuts as early as September, leading to a 1.5% rally in the S&P 500 [1][10] - Powell's acknowledgment of persistent inflation, coupled with a focus on job growth, reassured investors about the Fed's readiness to intervene if economic momentum slows [1][10] - By the end of the week, traders raised their bets on a September rate cut, with odds exceeding 90% [1] Investor Sentiment - Investors interpreted Powell's remarks as a sign that tariff-related inflation is viewed as temporary, not a long-term concern, which has fueled optimism in equities [2][10] - With falling treasury yields and a returning risk appetite, equities are expected to continue gaining in the upcoming weeks [2] Stock Recommendations - Recommended stocks based on relative price strength include Pediatrix Medical Group (MD), Enova International (ENVA), Primoris Services Corporation (PRIM), SkyWest, Inc. (SKYW), and Agnico Eagle Mines Limited (AEM) [3][10] Stock Analysis Strategy - Investors should assess stocks based on earnings growth and valuation multiples, while also considering their performance relative to industry peers or benchmarks [4] - Underperforming stocks should be avoided, while those outperforming their sectors in price should be prioritized for potential returns [5] - Stocks that have outperformed the S&P 500 over the past 1 to 3 months and have solid fundamentals are ideal candidates for investment [6] Earnings Estimates - Positive estimate revisions for upcoming earnings are crucial; upward revisions typically lead to additional price gains [7] - Screening parameters include relative price changes over various time frames and positive current-quarter estimate revisions [8] Zacks Rank and Stock Performance - Only Zacks Rank 1 (Strong Buy) stocks, which have historically outperformed the S&P 500, are considered for investment [9] - Specific stocks highlighted include: - **Pediatrix Medical Group (MD)**: Market cap of $1.5 billion, 51.8% share price increase over the past year, and a 9.3% upward revision in earnings estimates [11][12] - **Enova International (ENVA)**: Market cap of $2.9 billion, 37.4% share price increase, and a 32.4% growth estimate for 2025 earnings [13][14] - **Primoris Services Corporation (PRIM)**: Market cap not specified, 107.7% share price increase, and a 20.7% growth estimate for 2025 earnings [15] - **SkyWest, Inc. (SKYW)**: Market cap of $4.8 billion, 60.4% share price increase, and a 28.1% growth estimate for 2025 earnings [16] - **Agnico Eagle Mines Limited (AEM)**: Market cap of $69 billion, 66% share price increase, and a 62.2% growth estimate for 2025 earnings [17][18]

Company Performance - Icon PLC reported quarterly earnings of $3.26 per share, exceeding the Zacks Consensus Estimate of $3.18 per share, but down from $3.75 per share a year ago, representing an earnings surprise of +2.52% [1] - The company posted revenues of $2.02 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.57%, although this is a decrease from year-ago revenues of $2.12 billion [2] - Over the last four quarters, Icon PLC has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Icon PLC shares have declined approximately 23% since the beginning of the year, contrasting with the S&P 500's gain of 7.3% [3] - The current Zacks Rank for Icon PLC is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $3.36 on revenues of $1.98 billion, and for the current fiscal year, it is $13.21 on revenues of $7.96 billion [7] - The outlook for the Medical Services industry, where Icon PLC operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]